Edition:
India

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

43.92USD
18 Jul 2019
Change (% chg)

$-0.21 (-0.48%)
Prev Close
$44.13
Open
$44.19
Day's High
$44.20
Day's Low
$43.53
Volume
540,439
Avg. Vol
3,723,228
52-wk High
$63.69
52-wk Low
$43.53

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small... (more)

Overall

Beta: 1.19
Market Cap(Mil.): $106,283.60
Shares Outstanding(Mil.): 1,639.93
Dividend: 0.39
Yield (%): 2.41

Financials

  BMY.N Industry Sector
P/E (TTM): 23.62 29.88 32.67
EPS (TTM): 2.74 -- --
ROI: 18.60 14.90 14.49
ROE: 30.97 16.02 15.79

AbbVie looks beyond Humira with $63 billion deal for Botox-maker Allergan

Drugmaker AbbVie Inc said on Tuesday it would acquire Allergan Plc for about $63 billion, giving AbbVie control over the lucrative wrinkle treatment Botox and buying time to seek new growth before its blockbuster arthritis treatment Humira loses U.S. patent protection. | Video

26 Jun 2019

UPDATE 7-AbbVie looks beyond Humira with $63 bln deal for Botox-maker Allergan

June 25 Drugmaker AbbVie Inc said on Tuesday it would acquire Allergan Plc for about $63 billion, giving AbbVie control over the lucrative wrinkle treatment Botox and buying time to seek new growth before its blockbuster arthritis treatment Humira loses U.S. patent protection.

26 Jun 2019

AbbVie looks beyond Humira with $63 billion deal for Botox-maker Allergan

Drugmaker AbbVie Inc said on Tuesday it would acquire Allergan Plc for about $63 billion, giving AbbVie control over the lucrative wrinkle treatment Botox and buying time to seek new growth before its blockbuster arthritis treatment Humira loses U.S. patent protection. | Video

26 Jun 2019

Deals of the day-Mergers and acquisitions

June 24 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:

25 Jun 2019

Bristol-Myers plans to divest Celgene's psoriasis drug

Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal.

24 Jun 2019

UPDATE 3-Bristol-Myers plans to divest Celgene's psoriasis drug, shares slide

June 24 Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasis treatment Otezla to allay concerns raised by U.S. antitrust regulators, and pushed back the closing of their $74 billion deal.

24 Jun 2019

Bristol-Myers plans to divest Celgene's psoriasis drug

Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal.

24 Jun 2019

Bristol to divest Celgene's psoriasis treatment in FTC clearance push

June 24 Bristol-Myers Squibb Co said on Monday it would divest Celgene Corp's psoriasis treatment Otezla as the companies look to gain approval for their $74 billion deal from the U.S. Federal Trade Commission (FTC).

24 Jun 2019

Investor Ackman opposes United Technologies' aerospace merger with Raytheon - source

Billionaire investor William Ackman's activist hedge fund Pershing Square Capital Management LP is opposing United Technologies Corp's planned $120 billion aerospace merger with defence contractor Raytheon Co, a person familiar with the matter said on Tuesday.

12 Jun 2019

Investor Ackman opposes United Technologies' aerospace merger with Raytheon: source

Billionaire investor William Ackman's activist hedge fund Pershing Square Capital Management LP is opposing United Technologies Corp's planned $120 billion aerospace merger with defense contractor Raytheon Co, a person familiar with the matter said on Tuesday.

12 Jun 2019

Earnings vs. Estimates